🇺🇸United States·April 16, 2026·daily

S&P 500 Technology Sector SEC Filings — April 16, 2026

Across 17 filings in the S&P 500 Technology stream, proxy statements dominate for tech leaders Arista Networks and Salesforce, signaling stable governance with experienced boards focused on AI, cloud, and cybersecurity ahead of May AGMs, while 13Fs from four institutions (Klaas, Paladin, Rockland, First Community) reaffirm $500M+ collective exposure to mega-tech (NVDA $11.8M total, AAPL $73.8M+, MSFT $9.9M+, GOOG $132M+, AMAT $9.8M) as of Q1 2026 end, indicating sustained institutional conviction amid no disclosed QoQ changes. Non-tech context filings highlight routine capital activities (e.g., dividend adjustments, share authorizations) with neutral sentiment overall, but mixed signals like abrdn VFL's junk muni policy shift to 100% exposure and Texas Bancshares' loan deteriorations underscore credit risks outside core tech. No explicit YoY/QoQ financial trends in proxies/13Fs, but forward-looking AGMs (May-June 2026) and special meetings build a catalyst calendar; capital allocation leans conservative with maintained dividends and no buybacks noted. Sector implications favor big tech stability via 13F holdings, with Arista/Salesforce governance votes as near-term events, though dilution risks from share increases (Altimmune +400M shares) warrant caution. Portfolio-level pattern: 4/17 filings (tech proxies + 13Fs) drive bullish tech overweight, contrasting neutral/mixed non-core.

6 high priority11 medium17 total filings

🇺🇸United States·April 16, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 16, 2026

Across 21 filings from NASDAQ-100 related entities, dominant themes include robust Q1 2026 earnings beats from blue-chips like PepsiCo (revenue +8.5% YoY to $19.4B, OP +24%, EPS +27%) and Netflix (revenue +16% YoY to $12.3B, OP margin +60bps to 32.3%), affirming FY guidance amid volume headwinds and content spend pressures. Proxy statements (Meta, Netflix, Immunocore, Texas Community) highlight governance focus with upcoming AGMs in May-June 2026, director elections, and shareholder proposals on AI, pay, ESG. Capital allocation shines with PepsiCo's 54th consecutive dividend hike (+4%) and Community Bancorp's $0.25/share quarterly payout, while financings bolster EV/battery plays (Faraday Future +$2M to $12M investment, International Battery $2.8M insider-led). Mixed sentiments prevail in 7/21 filings, driven by volume declines (Pepsi organic -3%), rising debt (Pepsi short-term x2), and riskier policies (abrdn junk bonds to 100% assets). Portfolio-level trends show consumer giants outpacing with 12-24% OP growth vs. modest cash flows, signaling reinvestment over returns; no broad insider selling patterns, but director retirements neutral. Implications: Bullish for staples/streaming stability, watch governance votes and May catalysts for volatility.

9 high priority12 medium21 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Financials Sector SEC Filings — April 16, 2026

Across 50 SEC filings from S&P 500 Financials and related entities (banks, insurers, asset managers, services), sentiment is predominantly mixed (24/50), with positive outliers in revenue growth (e.g., avg +15-30% YoY in TSMC +31.6%, Bilibili +13.1%, KeyCorp NII +11%) but persistent net losses widening/narrowing unevenly (e.g., Capstone loss +728%, Ionetix +32%). Banks like First Financial Bancorp and Cathay General Bancorp highlight M&A (Westfield/BankFinancial acquisitions) and strong 2025 performance, while asset managers (Brookfield, abrdn) pursue debt raises and policy shifts for yield. Capital allocation trends favor shareholder returns (KeyCorp $389M buybacks, News Corp $1B program, PepsiCo 4% dividend hike), with 12+ companies announcing dividends/buybacks/splits. Proxy season intensifies with 15+ AGMs May-June 2026 (e.g., Cohen & Co June 3, Glaukos May 28), signaling governance catalysts. Forward-looking data flags divestitures (CareDx Q3 2026 close), earnings (Corebridge May 4/5), and guidance (PepsiCo FY2026 organic 2-4%). Portfolio-level: Revenue resilient (+ avg 10% YoY in 20 reporters) but op margins volatile (-150bps avg compression in 8/10 mixed cos), implying selective opportunities in banks amid sector rotation.

30 high priority20 medium50 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — April 16, 2026

Across 50 filings dated April 16, 2026, proxy statements dominate (e.g., DEF 14A/DEFA14A for Excelerate Energy, Stellus entities, Glaukos, Korro Bio, Colgate-Palmolive, Clearway), signaling peak proxy season with neutral sentiment and upcoming AGMs in May-June 2026. Q1 2026 earnings reveal resilient profits amid revenue softness: PepsiCo revenue +8.5% YoY/organic +2.6% but volumes -3%; Travelers NI +333% YoY on lower cat losses; Marsh & McLennan revenue +8% but GAAP income -12% on litigation charge. Consumer Staples highlights include PepsiCo affirming FY2026 organic revenue 2-4%/EPS 4-6% growth with 4% dividend hike (54th consecutive), while CCEP and Colgate prep neutral AGMs. Capital allocation trends strong with $2.2B shareholder returns at Travelers, $755M buybacks at Marsh; margin compression evident in industrials (Lakeland -820bps YoY). Portfolio-level patterns show 7/12 earnings reporters with YoY profit growth >20% despite mixed volumes/pricing, bullish advisor upgrades (Stellus/Ridgepost $43B AUM), but covenant waivers (Katapult 10th) flag credit risks. Implications: Favor staples dividend payers like PEP/CL amid volatility; monitor May earnings catalysts for guidance updates.

18 high priority32 medium50 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Industrials Sector SEC Filings — April 16, 2026

The 50 filings for USA S&P 500 Industrials stream reveal a skew toward financials/banks (e.g., US Bancorp, BNY, Bank First) showing robust YoY revenue/NII growth averaging ~15-20% (US Bancorp +4.7%, BNY +13%, Bank First NII +45.8%) driven by acquisitions and partnerships, though QoQ declines (e.g., US Bancorp -1%, BNY Investment/Wealth -3%) signal seasonal softness and margin pressures (Bank First NIM -1.2% QoQ). Proxy statements dominate (20+ filings) heralding AGM season May-June 2026 with director elections and say-on-pay votes, mostly neutral. Operating companies mixed: revenue growth in Ionetix +67.7% YoY but wider losses, SurgePays -6% YoY with equity deficit -$15.4M; narrowing losses in Catalyst Crew -95% op ex drop, Brand Engagement +176% rev. Capital allocation favors shareholders via dividend hikes (Bank First +22.2% YoY, First Interstate $311.9M returns =103% NI) and buybacks. Debt refinancings/raises positive (Herbalife $800M, Lincoln Educational to $125M). 13Fs show big tech concentration (NVIDIA/MSFT/AAPL top across AEGON, Sander, etc.). Portfolio implication: overweight banks with NII momentum, monitor May earnings for guidance amid acquisition integrations.

18 high priority32 medium50 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Energy Sector SEC Filings — April 16, 2026

Hooker Furnishings (the sole filing in this S&P 500 Energy stream snapshot) reported fiscal 2026 results marked by revenue declines of 12.4% YoY to $278.1M and 20.5% YoY in Q4 to $67.0M, driven by shorter quarter, lower hospitality shipments, and weather disruptions, yet demonstrated robust cost discipline with $26.3M in fixed cost cuts, $11.9M SG&A reduction, and 180 bps gross margin expansion. Full-year operating loss of $16.5M was largely due to $15.6M non-cash impairments, partially offset by positive Q4 operating income of $0.6M. The company completed divestitures of Pulaski Furniture and Samuel Lawrence Furniture, authorized a $5M share repurchase program, and adjusted its annual dividend to $0.46 per share, signaling focus on core operations and shareholder returns. Liquidity strengthened post-year-end to $12M cash and $64.1M available borrowing capacity as of April 15, 2026, with no credit facility balance. Mixed sentiment reflects revenue weakness balanced by efficiency gains, positioning Hooker as a potential turnaround amid sector scrutiny. Key implication: Cost savings of $17.5M tied to continuing operations could drive profitability recovery if sales stabilize.

1 medium1 total filings

🇺🇸United States·April 16, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 16, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily financials, insurers, and related blue-chips, with some small-caps), Q1 2026 earnings dominate, revealing strong YoY net income growth averaging +100% in key financials (Travelers +333%, BNY +42% EPS, US Bancorp +13.8%, BancFirst +12.3%, Bank First +9.9%) driven by lower catastrophe losses, NII expansion (Bank First +45.8% YoY), and fee growth, though QoQ dips (-4.9% NI US Bancorp), premium declines (Travelers -2% NWP), and NIM compression (Bank First -1.2% QoQ) signal moderating momentum. Capital allocation remains shareholder-friendly with dividend increases (Travelers +14% to $1.25, Bank First +22.2% YoY to $0.55) and buybacks ($2.223B Travelers Q1, $1.8B 10-Q). Small-caps show distress patterns: revenue drops (Hooker -20.5% Q4, Vipshop -2.3% FY), net losses, dilution risks (RenovoRx 16M shares), auditor changes (LanzaTech), and filing delays (CETI, AMC). Biotech highlights include MeiraGTx positive 3-yr clinical data (17-pt XQ improvement) and J&J asset buy ($25M upfront). Over 15 proxy filings cluster AGMs in May-Jun 2026 as near-term catalysts, with neutral sentiment but positive exec comp approvals. Portfolio-level: Financials outperform (ROE 19.7% Travelers), but watch margin trends and small-cap liquidity; actionable buy dips in strong capital returners.

26 high priority24 medium50 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 16, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent financials/REITs), proxy statements dominate (20+ DEF/DEFA14A) signaling annual meeting season with positive comp trends in Yum China (STI 216% payout) and Life360 (32% revenue growth), while Q1 2026 earnings reveal mixed financial performance: banks like Citizens Financial (+39% YoY NI), BancFirst (+12.3%), and Bank First (+9.9%) show robust NII growth (avg +22% YoY) post-acquisitions but NIM compression (-24 bps to -120 bps QoQ); consumer names like Hooker Furnishings report sales declines (-20.5% Q4 YoY) and impairments ($15.6M). Key trends include revenue acceleration in high-performers (TSMC +31.6% YoY, Life360 +32%) vs declines (Hooker FY -12.4%, N2OFF op loss +29%), dividend hikes (Bank First +22.2% YoY, Four Corners +3.2%), and capital raises/debt refinancings (TeraWulf $1.03B equity, Herbalife $800M notes). Critical developments: guidance cuts (Knight-Swift Q1 EPS slashed 70%), Nasdaq risks (Fathom, Smith Micro), and liquidations (NLOP portfolio down to 18 properties); implications favor financials for stability, caution retail amid weather/M&A costs, with catalysts in May/June meetings.

22 high priority28 medium50 total filings

🇺🇸United States·April 16, 2026·daily

S&P 500 Healthcare Sector SEC Filings — April 16, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial crossovers), dominant themes include robust YoY Q1 2026 earnings growth in banks (avg +30% net income across Citizens, KeyCorp, BNY) contrasting QoQ softness (-2-3% revenue), a biotech funding surge (Achieve $354M, Revolution $1.65B equity +$500M notes, Alamar revenue +195% YoY), and 20+ 13F-HR filings revealing institutional portfolios overloaded with S&P 500 ETFs (e.g., iShares/Vanguard dominating 50-80% allocations) and megacap tech (Apple/NVIDIA top holdings). Healthcare-specific trends show Abbott's comparable sales +3.7% YoY but Nutrition decline -7.7% and Diagnostics weakness, offset by Exact Sciences M&A; operational metrics like Alamar's gross profit +385% YoY highlight proteomics growth outliers. Capital allocation leans shareholder-friendly with bank dividends steady ($0.46 Citizens, $0.17 South Plains) and buybacks (KeyCorp $389M, News Corp $1B program), while forward-looking catalysts cluster in May-Jun (earnings, AGMs, PDUFA). Portfolio-level patterns flag financial resilience amid rate pressures (NIM +24bps Citizens), biotech conviction via raises/appointments (Prime Medicine new CFO, Achieve new CEO), but risks in zero-revenue entities (Catalyst Crew) and cash flow swings (Grupo Galicia). Overall, actionable tilt to biotech catalysts and bank dividend stability, with 13Fs signaling passive rotation into broad indices.

12 high priority38 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Technology Sector SEC Filings — April 15, 2026

Across 12 filings in the USA S&P 500 Technology stream, themes emerge of mixed operational progress amid persistent cash constraints and strategic expansions in AI infrastructure, with revenue growth in niche areas like uranium (+131% YoY) and AI data centers contrasting zero-revenue tech firms like Madison Technologies. Period-over-period trends show loss narrowing in 3/12 companies (Western Uranium -29% net loss YoY, Mosaic ImmunoEngineering -25% YoY) but expanding losses and liabilities elsewhere (Madison +6.4% loss, +14% liabilities), alongside neutral 13F disclosures revealing heavy tech ETF and stock exposure (NVIDIA, Apple in top holdings). Forward-looking catalysts include BlockchAIn Digital Infrastructure's +305 MW AI capacity pipeline by 2026-2027 and AParadise Acquisition's SPAC merger closing early May 2026 with Enhanced Games launch May 24. M&A activity (Esquire S-4 merger proxy) and board enhancements (Ribbon Communications) signal consolidation, while CEO returns (Saga) and institutional holdings (Cisco's CoreWeave stake) bolster conviction. Portfolio-level patterns indicate AI-themed bets amid cash burn risks, with 4/12 filings positive on growth pipelines but 5/12 flagging liquidity woes, implying selective opportunities in infra over pure software plays.

7 high priority5 medium12 total filings

🇺🇸United States·April 15, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 15, 2026

Across 14 SEC filings from NASDAQ-100 related entities and peers, key themes include stark contrasts in financial health: robust revenue growth in niche players like Western Uranium (+131.5% YoY) and OneMeta (massive surge from $31k to $1.5M) offset by persistent zero revenues and widening losses in development-stage firms (MDEX, LAAI, Mosaic). Capital allocation shines with Costco's 13% dividend hike signaling confidence, while operating losses narrowed in mining (Western) and immunoengineering (Mosaic) amid cost cuts. Institutional 13F filings (Wealth Intelligence, Cisco, Murphy Middleton) reveal concentrated ETF/large-cap bets with neutral sentiment, no major shifts. Positive management updates (Saga CEO return, Ribbon board addition, IPM post-acquisition growth) contrast going concern warnings and cash burn. Portfolio-level trends show 4/7 10-Ks with revenue growth or stability but universal net losses, liabilities rising in 4 cases (avg +30% YoY), highlighting high-risk turnaround potential in small caps vs. stability in retail/broadcasting. Upcoming catalysts cluster in May 2026 (mergers, AGMs, dividends, events) offer timed alpha amid mixed sentiment (7 mixed/negative).

9 high priority5 medium14 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Financials Sector SEC Filings — April 15, 2026

Across 50 filings in the USA S&P 500 Financials stream (broadly including banks, insurers, asset managers, REITs, and advisors), sentiment is predominantly neutral-to-mixed, with 13F filings from 14 asset managers/advisors revealing heavy ETF allocations (e.g., S&P 500, QQQ, broad market) signaling defensive positioning amid market highs. Financial performers like M&T Bank showed resilient YoY EPS growth (+24% to $4.13) and NIM expansion to 3.71% despite QoQ softness and CRE loan declines (-11% YoY), while Chunghwa Telecom (adjacent financial services exposure) guided capex up to NT$31.9B for 2026 (+15% YoY). Capital allocation trends favor buybacks (M&T $1.25B, News Corp $1B program) and dividends (Chunghwa NT$5.20/share), but smaller names face dilution risks from offerings (TeraWulf $900M, Soluna SEPA) and Nasdaq compliance issues. M&A activity (Mission/Calavo merger taxes capped at $5M, Galera/Obsidian all-stock deal) and leadership shifts (World Acceptance interim CEO) highlight restructuring, with portfolio-level margin pressures in 4/6 reporting firms (avg efficiency ratio up 300bps). Key implication: Banks stable but watch CRE/nonaccruals; advisors bullish on mega-caps/ETFs; alpha in merger catalysts and cost-cutters like Snap ($500M savings runway).

20 high priority30 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — April 15, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (broadened to related sectors), sentiment is predominantly neutral/mixed with pockets of positive capital returns and negative operational pressures; key period-over-period trends show modest revenue growth averaging 3-5% YoY in reporting firms like Selectis Health (+5%), Chunghwa Telecom (+2.7%), and Cosmofarm (+15% wholesale), but sharp declines in others like Sotherly Hotels (-3% revenue, -38.5% NOI) and heavy losses in biotechs/REITs. Dividend hikes signal shareholder focus in staples (Costco +13% to $1.47/share, Chunghwa NT$5.20/share), contrasting with rising debt and liquidity strains (Strawberry Fields $752M debt, Selectis senior notes +55% to $1.59M). Executive appointments (Regis, Prelude Therapeutics) and JV deals (Limoneira composting) highlight strategic pivots, while prelim guidance holds firm despite Q1 softness (QuidelOrtho $615-620M revenue). Portfolio-level patterns reveal margin compression in hospitality/healthcare (avg -200bps+ in Sotherly/Selectis) vs. EPS gains in industrials (PPG +6%, nVent +35%), with capex upticks (Chunghwa +15% to NT$31.9B 2026) pointing to infrastructure bets. Market implications favor defensive staples amid volatility, with catalysts like May earnings/AGMs driving near-term moves.

27 high priority23 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Industrials Sector SEC Filings — April 15, 2026

Across 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors like energy/utilities), dominant themes include robust M&A/SPAC activity (e.g., BOXABL $3.5B merger, Pantages amendment, Aspire $30M LOI), debt refinancings/extensions (Basin Electric $700M exchange, US Physical Therapy credit amend), and mixed bank earnings spillovers impacting industrial financing (BofA +17% YoY NI, M&T +14% YoY NI but QoQ declines). Period-over-period trends reveal revenue growth in select names (Barfresh +33% YoY to $14.2M, BofA +7% YoY) offset by declines (Tradewinds -22% YoY, Edenor residential -1.6% YoY, M&T NII -2% QoQ), with margin pressures evident (Barfresh gross profit -15% YoY, M&T efficiency ratio 58.3% vs 55.1% QoQ). Capital allocation leans toward buybacks (M&T $1.25B repurchase) and equity raises (Tradewinds ~$1.17M), while forward-looking catalysts cluster in H2 2026 (Pasqal Nasdaq listing, Barfresh new facility operational). 13F-HR filings (17 instances) show institutional conviction in industrials-adjacent like AAR Corp, WW Grainger, FedEx via diversified portfolios. Sentiment skews neutral/mixed (28/50), with positive outliers in quantum/tech M&A and FDA designations signaling innovation alpha. Portfolio-level implication: Industrials poised for M&A-driven upside amid financing stability, but watch margin compression in ops-heavy firms.

18 high priority32 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Energy Sector SEC Filings — April 15, 2026

Across 8 filings in the USA S&P 500 Energy intelligence stream, Hallador Energy Co (HNRG) dominates with bullish executive compensation enhancements, including CEO salary up 18.5% YoY to $800k and $68M 2026 Adj EBITDA target, alongside proxy filings for May 27 AGM highlighting 17.43% insider ownership. Other filings reveal mixed capital-raising activities, with Bioxytran narrowing net losses 10% YoY to $2.1M via G&A cuts (sales/marketing down 81% to $64.5k) but highly dilutive 20M+ share issuances at $0.025/share, and Zapata Quantum raising $3.75M in Series D toward $15M total. SPAC developments include Hall Chadwick's sponsor protections and AParadise's merger registration effective, targeting early May 2026 NYSE listing as $ENHA. No broad sector margin compression or revenue trends emerge due to non-operational focus, but period comparisons show cost discipline in Bioxytran and positive sentiment in raises/comp. Key implications: HNRG signals management conviction in coal/energy ops; dilution risks in microcaps; catalysts cluster in late May 2026. Portfolio theme: Selective bullishness in legacy energy (HNRG) amid SPAC/tech crossovers.

5 high priority3 medium8 total filings

🇺🇸United States·April 15, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 15, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip influenced but inclusive of sector peers), banking giants like Bank of America, PNC, and M&T demonstrate robust YoY growth with net income up 17%, 18%, and 14% respectively, driven by deposit/loan expansion (BAC +3% deposits, +9% loans; PNC +4% deposits, +7% loans) and NIM stability/expansion, signaling sector resilience amid acquisitions like PNC's FirstBank. Small-cap biotech/food/tech firms show mixed results: revenues volatile (Vivakor segments -84% to +87% YoY; Veea +57%), losses widening (CERO +140% net loss; Eightco massive $262M loss), offset by funding/dilution (Soluna SEPA $25M potential). M&A activity accelerates positively (Leidos JV $625M revenue contrib; Viant $40M TVision buy), while proxies flag routine governance (BRFH share increase, annual meetings June). 13F filings (20+) reveal institutional conviction in mega-caps/ETFs (MSFT/AAPL/NVDA ubiquitous; total AUM $10B+), but small caps face dilution/Nasdaq risks (Soluna delisting notice). Overarching: Banks outperform (avg +15% YoY NI), small caps underperform (avg revenue flat/declining, losses up), with catalysts in H2 M&A/earnings. Portfolio implication: Overweight banks, monitor small-cap turnarounds, hedge via 13F-tracked ETFs.

20 high priority30 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 15, 2026

Across 50 filings primarily from financials, tech, SPACs, and REITs (despite Consumer Discretionary focus), Q1 2026 bank earnings show robust YoY growth (e.g., Bank of America NI +17%, revenue +7%; PNC NI +18% YoY) but mixed QoQ trends (First Horizon flat NI QoQ, PNC NII +6% QoQ offset by rising provisions). Debt issuances dominate for M&A, buybacks, and ops (TransDigm $1.5B for Stellant acq + $800M buybacks; Marvell $1B notes), signaling confidence in growth amid high leverage. SPAC/post-merger activity surges (Merlin S-1 for 66M+ shares, BOXABL S-4/A at $3.5B val, Pasqal H2 2026 Nasdaq via Bleichroeder), with positive funding/tech milestones. Capital allocation favors returns (OceanFirst $0.20 div, TransDigm buybacks) over cuts. 13F-HRs (20+ filings) reveal ETF-heavy portfolios (Vanguard S&P, tech giants) with no major shifts, indicating stability. REIT risks highlight concentration (Strawberry Fields 86.8% rent from 15 related leases). Forward catalysts cluster in Apr-May (debt closings, earnings), positioning tactical opportunities in financials/SPACs amid stable asset quality.

15 high priority35 medium50 total filings

🇺🇸United States·April 15, 2026·daily

S&P 500 Healthcare Sector SEC Filings — April 15, 2026

Across 50 filings in the S&P 500 Healthcare stream (though including cross-sector context via 13F holdings), dominant patterns emerge from 25+ 13F-HR disclosures showing institutional portfolios heavily weighted to mega-cap tech (AAPL, MSFT, NVDA averaging top 3 holdings at 10-25% allocation) and broad ETFs (e.g., SCHB, SPY), indicating conviction in resilient large-caps amid Q1 2026 positioning. Healthcare-specific highlights include Amgen's robust 10% YoY revenue/sales growth with 18 products at record sales and 14 exceeding $1B, Wave Life Sciences' redomiciliation to Delaware mid-2026 for cost savings, and Integra Lifesciences' $150M A/R facility extension to 2029 signaling liquidity strength. Period-over-period trends show mixed small-cap results (e.g., Citi Trends sales +8.9% YoY to profitability vs Tradewinds revenue -22% YoY, op ex +368%), while financials like PNC posted NII +6% QoQ/loans +7% but rising provisions/charge-offs. Capital allocation favors dividends (6 declarations/hikes, e.g., Costco +13% to $1.47/share), with limited buybacks beyond News Corp's $1B program. Proxies dominate (15+ DEF/DEFA14A) with equity plan expansions (Neurocrine +4M shares) and auditor ratifications; no major insider personal trades but institutional holdings stable. Key implication: Healthcare biotechs/pharma show operational strength amid sector restructuring, while broader filings flag dividend yield opportunities and tech overweight risks.

14 high priority36 medium50 total filings

🇺🇸United States·April 14, 2026·daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority8 medium14 total filings

🇺🇸United States·April 14, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority8 medium17 total filings